Anna Komorowski, MD
Hematology · Nyack, NYNPI 1902848567
Payments from drug & device makers
What this record shows
This record is dominated by education: $487 of the $735 with a category attached, or 66.2%. It is spread thinly across 11 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2019 at $404 and has fallen 67.8% since, to $130 in 2024. That places this record below the midpoint for hematology clinicians in NY, where the typical reported total is $619.
Across 19 payments — averaging $38.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$160
- Genentech USA, Inc.$123
- Amgen$121
- Exelixis Inc.$100
- Incyte Corporation$100
- AstraZeneca$30
- plus $101 from 5 others
Across 2 payments — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
What the payments were for
- Food & beverage$24934%
- Education$48766%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $160 |
| Genentech USA, Inc. | 3 | $123 |
| Amgen | 2 | $121 |
| Exelixis Inc. | 1 | $100 |
| Incyte Corporation | 1 | $100 |
| AstraZeneca | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Seagen Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| GE HealthCare | 1 | $17 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$122
How this compares
$735 in reported general payments places this provider in the 50th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 51 | $788,331 |
| VerzenioAbemaciclib | 22 | $345,698 |
| LonsurfTrifluridine/Tipiracil Hcl | 21 | $128,503 |
| EliquisApixaban | 35 | $39,568 |
| XareltoRivaroxaban | 15 | $19,852 |
| Exemestane | 33 | $5,193 |
| Anastrozole | 102 | $2,679 |
| Letrozole | 68 | $1,485 |
| Hydroxyurea | 32 | $1,001 |
| Tamoxifen Citrate | 27 | $929 |
| Levothyroxine Sodium | 38 | $642 |
| Olanzapine | 22 | $605 |
| Gabapentin | 33 | $477 |
| Mirtazapine | 16 | $281 |
| Minoxidil | 18 | $280 |
Paid to pharmacies, not to this prescriber.
Other hematology in Nyack
- Bradley CohenNyack$9K
- Mathew LonbergNyack$8K
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.